CGIX - Cancer Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.1096
+0.0026 (+2.43%)
As of 2:27PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.1070
Open0.1071
Bid0.1093 x 1200
Ask0.1097 x 800
Day's Range0.1007 - 0.1099
52 Week Range0.0900 - 1.2500
Volume1,233,159
Avg. Volume2,480,876
Market Cap6.621M
Beta (3Y Monthly)2.04
PE Ratio (TTM)N/A
EPS (TTM)-0.5150
Earnings DateAug 20, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Cancer Genetics Reports Second Quarter 2019 Financial Results and Provides Strategic Business Update

    RUTHERFORD, N.J., Aug. 20, 2019 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For July 16, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Capricor Therapeutics, Inc.  (NASDAQ: CAPR ...

  • Benzinga

    Cancer Genetics Sharply Higher After Interpace Buys Biopharma Unit

    Cancer Genetics (NASDAQ: CGIX ) shares are trading sharply higher after Interpace Diagnostics (NASDAQ: IDXG ) said it purchased the Biopharma Services unit of the Cancer Genetics. Interpace Diagnostics ...

  • GlobeNewswire

    Cancer Genetics, Inc. Announces Strategic Transactions

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the sale of its BioPharma business. The Company’s junior secured lender, Partners for Growth IV, L.P. (“PFG”) conducted a consensual private foreclosure of the assets relating to the Company’s BioPharma business under Article 9 of the Uniform Commercial Code and sold them to Interpace Diagnostics Group Inc. (IDXG).

  • GlobeNewswire

    Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners

    Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or the “Company”), announced today that it has acquired assets and certain liabilities constituting the Biopharma Services business of Cancer Genetics, Inc. (CGIX) (the “BioPharma Business”) for approximately $23.5 million subject to certain adjustments. The acquisition is expected to create a leading oncology testing and service company in the clinical diagnostic and Biopharma markets, leveraging sophisticated assays, novel algorithms and custom service capabilities across the continuum of oncology from precancerous assessment to drug discovery and clinical trial support. In conjunction with this acquisition Ampersand Capital Partners, one of the leading private equity firms in the diagnostic/biopharma sector, agreed to invest $27M in Interpace in two tranches of newly issued convertible preferred stock, a portion of which will be subject to approval by Interpace’s shareholders.

  • Triangle pharma brings in new CFO looking for capital
    American City Business Journals

    Triangle pharma brings in new CFO looking for capital

    Amidst a continued effort to expand, Innovate BioPharmaceuticals has brought on a full-time chief financial officer, which it hopes will lead a campaign to raise more capital to finance its clinical trials.

  • GlobeNewswire

    Innovate Biopharmaceuticals Expands Its Management team with the Addition of Ed Sitar as Its Chief Financial Officer

    Innovate Biopharmaceuticals, Inc. (INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced the appointment of Ed Sitar as its Chief Financial Officer commencing on July 1, 2019. With an expanded management team, Innovate intends to focus on non-dilutive sources of capital to further develop its pipeline, including out-licensing of (i) selective ex-US rights to INN-202 for celiac disease and (ii) Innovate’s earlier clinical stage pipeline of drug product candidates.  In addition, Innovate intends to suspend future sales of shares under its “at-the-market” established pursuant to its common stock sales agreement with H.C. Wainwright & Co., LLC and Ladenburg Thalmann & Co. Inc.

  • LabCorp (LH) Closes Envigo Swap Deal, Expands in CRO Space
    Zacks

    LabCorp (LH) Closes Envigo Swap Deal, Expands in CRO Space

    The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.

  • Associated Press

    Cancer Genetics: 1Q Earnings Snapshot

    The Rutherford, New Jersey-based company said it had a loss of 9 cents per share. Losses, adjusted for costs related to mergers and acquisitions, were 8 cents per share. The diagnostics company posted ...

  • GlobeNewswire

    Cancer Genetics Reports First Quarter 2019 Financial Results and Provides Strategic Business Update

    RUTHERFORD, N.J., May 20, 2019 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through diagnostics,.

  • Associated Press

    Cancer Genetics: 4Q Earnings Snapshot

    On a per-share basis, the Rutherford, New Jersey-based company said it had a loss of 14 cents. The diagnostics company posted revenue of $6.8 million in the period. For the year, the company reported that ...

  • GlobeNewswire

    Cancer Genetics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Strategic Business Updates

    RUTHERFORD, N.J., April 16, 2019 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through diagnostics,.

  • Investors Who Bought Cancer Genetics (NASDAQ:CGIX) Shares Five Years Ago Are Now Down 98%
    Simply Wall St.

    Investors Who Bought Cancer Genetics (NASDAQ:CGIX) Shares Five Years Ago Are Now Down 98%

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Long term investing is the way to go, but thatRead More...

  • Could The Cancer Genetics, Inc. (NASDAQ:CGIX) Ownership Structure Tell Us Something Useful?
    Simply Wall St.

    Could The Cancer Genetics, Inc. (NASDAQ:CGIX) Ownership Structure Tell Us Something Useful?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who reallyRead More...

  • GlobeNewswire

    Cancer Genetics, Inc. Announces Closing of Public Offering of Common Stock

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the closing and funding of its previously announced public offering of 15,217,392 shares of its common stock ("Common Stock") at a public offering price of $0.23 per share.

  • Benzinga

    The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 28) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...

  • GlobeNewswire

    Cancer Genetics, Inc. Announces Pricing of $3.5 Million Public Offering of Common Stock

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the pricing of a public offering of 15,217,392 shares of its common stock, offered at a price to the public of $0.23 per share, for gross proceeds of approximately $3.5 million, before deducting placement agent fees and other offering expenses payable by Cancer Genetics. The offering is expected to close on or about January 31, 2019, subject to customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

  • GlobeNewswire

    Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in a public offering. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.  The offering is being conducted as a “best efforts” offering and the placement agent is not obligated to purchase any securities. Cancer Genetics intends to use the net proceeds from this offering to pay any amounts we are required to pay to our lenders, and if any proceeds remain available, to pay certain costs previously incurred by us in connection with our strategic initiatives and to fund working capital and other general corporate purposes.

  • Benzinga

    Insider Buys Of The Week: Cancer Genetics, Dish Network, Valvoline

    Another CEO and fellow insiders took advantage of an offering of common shares. Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. A DISH Network Corp (NYSE: DISH) executive vice president purchased added another 25,000 shares of this pay-TV provider early last week.

  • GlobeNewswire

    Cancer Genetics Issues Letter to Shareholders

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today published a letter to shareholders from its Chief Executive Officer, Jay Roberts. Happy New Year – we are pleased to provide an update on our activities and strategic development.  We believe that 2018 was an important time for re-assessing our corporate direction, consolidating our company operations and focusing our capabilities in our biopharma business to execute our restructuring, while focusing on revenue growth and accelerating our path to profitability.

  • Benzinga

    The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks The following biotech stocks struck 52-week highs Jan. 9:  China SXT Pharmaceuticals Inc (NASDAQ: SXTC ...

  • GlobeNewswire

    Cancer Genetics, Inc. Announces Pricing of Public Offering of Common Stock

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a price to the public of $0.225 per share. Cancer Genetics also granted the underwriter a 45-day option to purchase up to an additional 2,000,000 shares of its common stock at the public offering price of $0.225 per share, less underwriting discounts and commissions. Cancer Genetics expects to receive aggregate gross proceeds of approximately $3.0 million from the offering, assuming no exercise of the underwriter’s option to purchase additional shares.

  • GlobeNewswire

    Cancer Genetics Strengthens Management Team with Appointment of William Finger as Executive Vice President, Precision Medicine and Pharma Services

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the appointment of William Finger as the Company’s Executive Vice President, Precision Medicine and Biopharma Solutions, effective immediately. Mr. Finger will be responsible for developing and overseeing Cancer Genetics’ Precision Medicine and Biopharma and Clinical Trial business unit.